Author information:
(1)Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research 
Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
(2)Molecular Oncology Group, Cancer Research UK Manchester Institute, 
Manchester, UK.
(3)Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge 
Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
(4)Department of Pathological Anatomy, Bellvitge University Hospital, Bellvitge 
Biomedical Research Institute, L'Hospitalet, Barcelona, Catalonia, Spain.
(5)Medical Oncology Service, Catalan Institute of Oncology, Germans Trias i 
Pujol University Hospital, Badalona, Catalonia, Spain.
(6)Pathology Department, Germans Trias i Pujol University Hospital, Badalona, 
Catalonia, Spain.
(7)Medical Oncology Service, Vall d'Hebron University Hospital, Barcelona, 
Catalonia, Spain.
(8)Dermatology Service, Hospital La Fe, Universidad de Valencia, Valencia, 
Spain.
(9)Medical Oncology Service, Hospital General, Valencia, Spain.
(10)Department of Pathology, University Hospital of Uppsala, Uppsala, Sweden.
(11)Translational Cell &Tissue Pathology, Katholieke Universiteit Leuven, 
Leuven, Belgium.
(12)University College Dublin School of Biomolecular and Biomedical Science, 
University College Dublin Conway Institute, University College Dublin, Belfield, 
Dublin, Ireland.
(13)Center for Melanoma, Massachusetts General Hospital Cancer Center, Boston, 
Massachusetts.
(14)Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, Cambridge, 
UK.
(15)University of Manchester, Christie National Health Service Foundation Trust, 
Manchester, UK.
(16)1] Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research 
Institute, L'Hospitalet, Barcelona, Catalonia, Spain. [2] Department of 
Physiological Sciences II, School of Medicine, University of Barcelona, 
Barcelona, Catalonia, Spain. [3] Institucio Catalana de Recerca i Estudis 
Avançats, Barcelona, Catalonia, Spain.